In­done­si­a's state-owned phar­ma com­pa­ny strikes deal to man­u­fac­ture Mer­ck’s HPV vac­cine

Cer­vi­cal can­cer is the sec­ond most fre­quent form of can­cer among women in In­done­sia. In ad­di­tion to rais­ing aware­ness and en­cour­ag­ing women to get the HPV shot, the coun­try is now look­ing to man­u­fac­ture Mer­ck’s vac­cine.

The In­done­sian state-owned phar­ma­ceu­ti­cal com­pa­ny Bio Far­ma an­nounced on Tues­day it has signed a con­tract with Mer­ck to lo­cal­ly pro­duce the MSD 4-va­lent HPV vac­cine.

Ac­cord­ing to a trans­lat­ed news re­lease, Mer­ck and Bio Far­ma have had a re­la­tion­ship since 2016. While the HPV vac­cine is cur­rent­ly in use through­out the coun­try, the gov­ern­ment plans to scale up im­mu­niza­tions in 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER